News
HanchorBio Expands Next-Generation Immunotherapy Strategy by Integrating Immune Education and Macrophage Activation
HanchorBio announced the expansion of its immunotherapy strategy to explore vaccine-based immune activation approaches through strategic collaborations in cancer and immune-mediated diseases.
Aug 20, 2026
Read more
HanchorBio Announces HCB301 Oral Presentation and HCB101 Best Poster Selection at KSMO 2026
HanchorBio announced that three abstracts featuring its clinical-stage programs HCB101 and HCB301 have been accepted for presentation at KSMO 2026—the 19th Annual Meeting of the Korean Society of Medical Oncology and 2026 International Conference—held in conjunction with the 14th International Conference of the Federation of Asian Clinical Oncology (FACO), taking place September 2–4, 2026, in Seoul, Korea.
Aug 19, 2026
Read more
HanchorBio Advances HCB101 Macrophage-Directed Immunotherapy Strategy with First Patient Dosed in Global HNSCC Study
HanchorBio announced that the first patient has been dosed in Cohort 6b of its global Phase 1b/2a HCB101-201 study (NCT06771622)
Aug 17, 2026
Read more
HanchorBio Receives FDA Pre-IND Feedback Supporting Advancement of HCB303, a Next-Generation Trispecific Immunotherapy
HanchorBio announced that it has received written responses from the U.S. Food and Drug Administration (FDA) following a Type B pre-Investigational New Drug (pre-IND) submission for HCB303, the Company’s next-generation, first-in-class trispecific immunotherapy designed to simultaneously activate innate and adaptive antitumor immunity.
Aug 12, 2026
Read more
From Macrophage Biology to Clinical Development: HanchorBio Advances the Future of Gastric Cancer Immunotherapy
HanchorBio announced insights from the “Taiwan Gastric Cancer Experts Forum on Clinical Challenges and Emerging Immunotherapy”, held August 8–9 in Taichung, Taiwan.
Aug 10, 2026
Read more
HanchorBio and Taiwan Cancer Moonshot Team Led by Professor Sung-Liang Yu Establish Strategic Collaboration to Advance Precision Oncology
HanchorBio announced that its wholly owned Taiwan subsidiary has entered into a strategic collaboration with the research team led by Professor Sung-Liang Yu of National Taiwan University, a key participating team in the Taiwan Cancer Moonshot Program (TCMP). The collaboration has been formalized through a memorandum of understanding signed by HanchorBio Taiwan and Professor Yu’s team.
Aug 07, 2026
Read more
HanchorBio Invited to Present at the 9th BPD Biopharmaceutical Process Development Conference on Next-Generation Drug Manufacturing and CMC Development
HanchorBio announced that Vivian Kuo, PhD, Executive Director of CMC, has been invited to speak at the 2026 9th BPD Biopharmaceutical Process Development Conference.
Aug 05, 2026
Read more
HanchorBio Expands Clinical Evidence Supporting Its Macrophage-Directed Oncology Strategy
HanchorBio announced updated early clinical observations from its HCB101 program.
Jul 22, 2026
Read more
HanchorBio Brings Clinical Anchor-to-Platform Strategy to BIO Asia–Taiwan 2026
HanchorBio announced that it will present its clinical development and platform strategy at BIO Asia–Taiwan 2026, taking place July 16–19, 2026, in Taipei, Taiwan.
Jul 13, 2026
Read more
HanchorBio and InxMed Sign Strategic MOU to Explore HCB101-Based Combination Therapies for Difficult-to-Treat Solid Tumors
HanchorBio announced that its subsidiary, FBD Biologics Limited, has signed a strategic memorandum of understanding (“MOU”) with InxMed (Shanghai) Co., Ltd. (“InxMed”).
Jul 08, 2026
Read more